Clinical and Functional Characteristics of Atrial Fibrillation in Patients With and Without Ischemic Heart Disease

Main Article Content

Kaisar Moldash

JSC “Astana Medical University”, Astana, Kazakhstan

MoldashK@list.ru

Akerke Kalimbetova

National Emergency Medicine Coordination Center, Astana, Kazakhstan

JSC “Astana Medical University”, Astana, Kazakhstan

akerke.kalimbetova@gmail.com

Ayan Abdrakhmanov

National Emergency Medicine Coordination Center, Astana, Kazakhstan

JSC “Astana Medical University”, Astana, Kazakhstan

Ayan-3@mail.ru

Zhanasyl Suleimen

National Emergency Medicine Coordination Center, Astana, Kazakhstan

zhanasyls@gmail.com

Abstract

This article examines atrial fibrillation (AF) in patients with and without ischemic heart disease (IHD), focusing on their clinical and laboratory-instrumental characteristics. The study assessed anthropometric parameters (sex, age, weight, height, body mass index), AF types, primary and comorbid diagnoses, echocardiographic data (ejection fraction), lipid profile and biochemical markers (ALT, AST, total cholesterol, LDL), scores on the CHA₂DS₂-VASc and HAS-BLED scales, as well as data on surgeries and prescribed pharmacotherapy. The results indicate that patients with IHD more frequently present with persistent forms of AF, endomorphic body type, signs of endogenous obesity, consistently accompanying arterial hypertension, elevated CHA₂DS₂-VASc and HAS-BLED risk scores, and are prescribed a higher average number of medications, reflecting a more complex overall clinical status and requiring more meticulous long-term clinical supervision and careful adjustment of therapy according to dynamic patientrisk profiles.
The identified differences between groups highlight the necessity of a comprehensive and individualized approach to the diagnosis and treatment of atrial fibrillation, particularly in patients with ischemic heart disease.

Keywords:
atrial fibrillation, coronary artery disease, arterial hypertension, hypercholesterolemia, hemorrhage, thrombosis

Article Details

Received 2025-11-10
Accepted 2026-01-28
Published 2026-03-31

References

World Health Organization. Noncommunicable Diseases Country Profiles: Kazakhstan. Geneva: WHO; 2025. Available online: https://www.who.int/europe/news/item/28-07-2025-kazakhstan-s-progress-in-tackling-cardiovascular-diseases-and-cancer-highlighted-in-who-report#:~:text=NCDs%20%E2%80%93%20including%20cardiovascular%20diseases%2C%20cancer,from%2031%20to%2049%20nationwide (accessed on 10 November 2025).

World Health Organization. Global Status Report on Noncommunicable Diseases. Geneva: WHO; 2025. Available online: https://www.who.int/publications/i/item/9789240105775#:~:text=The%20World%20Health%20Organization's%20(WHO)%202025%20Noncommunicable,*%20Policy%20implementation%20*%20Health%20system%20responses (accessed on 10 November 2025).

Cheng S., He J., Han Y., Han S., Li P., Liao H., Guo J. Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021. Europace. – 2024. – Vol. 26(7). – P. euae195. https://doi.org/10.1093/europace/euae195

Ahmetnijaz L.M., Sarsenbaeva G.E., Zhaksalykova G.B., Kenesova A.A., Kulkaeva G.U., Shalhiev S.S., Karashutova Zh.N., Il'jasova Zh.R., Rakisheva D.M., Kenzhekulova R.N., Magavina A.M., Kul'matova A.R., Zhanijazova G.A., Talgatova A.B. Zdorov'e naselenija Respubliki Kazahstan i dejatel'nost' organizacij zdravoohranenija v 2024 godu. Statisticheskij sbornik (Health of the population of the Republic of Kazakhstan and the activities of healthcare organizations in 2024), Astana, 2024. Available online: https://pharmreviews.kz/images/document/2025/sbornik-2024.pdf. (accessed on 10 November 2025). In Russian.

Tlegenova Zh.Sh., Zholdin B.K., Kudaiberdieva G.Z., Abdrakhmanov A.S., Grzhibovsky A.M. Prevalence of atrial fibrillation and associated factors in patients with arterial hypertension in primary care settings. Science & Healthcare. – 2019. – Vol. 21(2). – P. 44-54. https://doi.org/10.34689/SH.2019.21.2.005

Taghdiri A. Inflammation and arrhythmogenesis: a narrative review of the complex relationship. International Journal of Arrhythmia. – 2024. – Vol. 25. – P. 4. https://doi.org/10.1186/s42444-024-00110-z

Hindricks G., Potpara T., Dagres N., Arbelo E., Bax J.J., Blomstrom-Lundqvist C., Boriani G., Castella M., Dan G.-A., Dilaveris P.E., Fauchier L., Filippatos G., Kalman J.M., Meir M.L. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). – 2020. – Vol. 42(5). – P. 373–498. https://doi.org/10.1093/eurheartj/ehaa612

European Society of Cardiology. 2024 ESC Guidelines for the diagnosis and management of atrial fibrillation: Essential messages. European Society of Cardiology, 2024. Available online: https://www.escardio.org/static- file/Escardio/Guidelines/Products/Essential%20Messages/2024%20EM/Essential%20Messages_2024%20AFib.pdf. (accessed on 10 November 2025).

Van Gelder, I. C., Rienstra, M., Bunting, K. V., Casado-Arroyo, R., Caso, V., Crijns, H. J. G. M., De Potter, T. J. R., Dwight, J., Guasti, L., Hanke, T., Jaarsma, T., Lettino, M., Løchen, M. L., Lumbers, R. T., Maesen, B., Mølgaard, I., Rosano, G. M. C., Sanders, P., Schnabel, R. B., Suwalski, P., … ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European heart journal. – 2024. – Vol. 45(36). – P. 3314–3414. https://doi.org/10.1093/eurheartj/ehae176

Sha R., Baines O., Hayes A., Tompkins K., Kalla M., Holmes A.P., O’Shea C., Pavlovic D. Impact of Obesity on Atrial Fibrillation Pathogenesis and Treatment Options. J. Am. Heart Assoc. – 2023. – Vol. 13(1). – P. e032277. https://doi.org/10.1161/JAHA.123.032277

Zhao X., Wang D., Qin L. Lipid profile and prognosis in patients with coronary heart disease: a meta‑analysis of prospective cohort studies. BMC Cardiovascular Disorders. – 2021. – Vol. 21. – P. 69. https://doi.org/10.1186/s12872-020-01835-0

Serna M.J., Rivera‑Caravaca J.M., López‑Gálvez R., Soler‑Espejo E., Lip G.Y.H., Marín F., Roldán V. Dynamic assessment of CHA₂DS₂‑VASc and HAS‑BLED scores for predicting ischemic stroke and major bleeding in atrial fibrillation patients. Rev. Esp. Cardiol. – 2024. – Vol. 77(10). – P. 835–842. https://doi.org/10.1016/j.rec.2024.02.011

Zhao X., Wang D., Qin L. Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. – 2021. – Vol. 21. – P. 69. https://doi.org/10.1186/s12872-020-01835-0